Zydus Subsidiary Completes Euro 700,000 Acquisition of French Medical Distributor
Zydus Lifesciences announced the completion of its subsidiary Amplitude SAS's acquisition of FBC Medical, a French medical equipment distributor, for Euro 700,000. The transaction involves 100% share capital acquisition of the company incorporated in 2016, which has maintained consistent turnover of around Euro 935,000. The strategic acquisition aims to internalize commercial capabilities and reduce long-term selling and distribution costs by eliminating third-party commission fees.
*this image is generated using AI for illustrative purposes only.
Zydus life science has completed the acquisition of FBC Medical through its subsidiary Amplitude SAS, as disclosed in regulatory filings submitted to stock exchanges on May 1, 2026. The pharmaceutical company's indirect wholly owned subsidiary acquired complete ownership of the French medical equipment distributor for Euro 700,000.
Transaction Overview
Amplitude SAS purchased 100% share capital of FBC Medical, a simplified joint stock company registered in France. The acquisition was completed on April 30, 2026, through cash consideration.
| Parameter: | Details |
|---|---|
| Acquisition Cost: | Euro 700,000 |
| Shares Acquired: | 5,000 shares of Euro 1 each |
| Shareholding: | 100% of entire share capital |
| Transaction Date: | April 30, 2026 |
| Consideration Type: | Cash consideration |
Target Company Profile
FBC Medical operates as a specialized distributor of medical equipment with its registered office located at 8 Allée Jean-Marie Deguignet, 35850 GEVEZE, France. The company was incorporated in 2016 and maintains an exclusive sales agency agreement with Amplitude for French departments 35, 22, 29, and 56 across the entire territory of each department.
Financial Performance
The target entity demonstrates consistent financial performance with steady turnover based on audited financial statements:
| Year: | Turnover (Euro) |
|---|---|
| 2025: | 935,000 |
| 2024: | 951,000 |
| 2023: | 924,000 |
FBC Medical maintains an authorized and paid-up share capital of Euro 5,000, divided into 5,000 equity shares of Euro 1 each.
Strategic Rationale
The acquisition serves to internalize commercial capabilities currently outsourced to third-party sales agents. By acquiring and integrating FBC Medical, Amplitude expects to eliminate ongoing commission and business-development fees, thereby reducing long-term selling and distribution costs.
Regulatory Compliance
Zydus Lifesciences disclosed that the acquisition does not fall within related party transactions, with no promoter, promoter group, or group companies having any interest in the target entity. The transaction required no governmental or regulatory approvals, facilitating smooth completion.
The acquisition details were disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring full transparency with stakeholders and regulatory authorities.
Source: None/Company/INE010B01027/1173260afd29452f.pdf
Historical Stock Returns for Zydus Life Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.17% | -4.65% | +3.58% | -8.50% | +1.59% | +57.99% |
Will Zydus Lifesciences pursue similar acquisitions of other third-party distributors in France or expand this internalization strategy to other European markets?
How much in annual commission savings does Zydus expect to achieve from eliminating FBC Medical's third-party fees, and what will be the payback period for this €700,000 investment?
Could this acquisition signal Zydus's broader pivot toward direct distribution models in international markets rather than relying on local sales agents?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
